The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of NOXXON. NOXXON disavows any obligation to update or correct the information contained in these publications.

Deng L, Stafford JH, Liu SC, Chernikova SB, Merchant M, Recht L, Martin Brown J.
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI.
Neoplasia. 2017, 19(1), 1-7.
read abstract on

Zboralski D, Hoehlig K, Eulberg D, Froemming A, Vater A.
Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade.
Cancer Immunol Res. 2017.
read article on

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Br J Haematol. 2017, 179(1), 36.
read abstract on

Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ.
Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
Am J Pathol. 2017.
read article on

Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
Clin Immunol. 2016.
read abstract on

Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Więcek A, Haller H.
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.
Nephrol Dial Transplant. 2016.
read article on

Hoehlig K, Klussmann S.
Spiegelbildliche Nukleinsäuren als pharmakologische Wirkstoffe.
Chemie in unserer Zeit 2015, 49(6), 422-5.
read abstract on

Hoehlig K, Klussmann S.
Molekulare Schere.

Chemie in unserer Zeit
2015, 49(6), 421.
read abstract on

Kalnins A, Thomas MN, Andrassy M, Müller S, Wagner A, Pratschke S, Rentsch M, Klussmann S, Kauke T, Angele MK, Bazhin AV, Fischereder M, Werner J, Guba M, Andrassy J.
Spiegelmer Inhibition of MCP-1/CCR2 - Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
Scand J Immunol. 2015, 82(2), 102.
read abstract on

Brockmann C, Brockmann T, Dege S, Busch C, Kociok N, Vater A, Klussmann S, Strauß O, Joussen AM.
Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.
Graefes Arch Clin Exp Ophthalmol. 2015.
read abstract on

Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C.
Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.
Nature Commun. 2015, 6, 6923.
read article on

Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A.
Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.
Nature Commun. 2015, 6, 6481.
read article on

Mavroidis M, Davos CH, Psarras S, Varela A, C Athanasiadis N, Katsimpoulas M, Kostavasili I, Maasch C, Vater A, van Tintelen JP, Capetanaki Y.
Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy.
Basic Res Cardiol. 2015, 110(3), 485.
read abstract on

Haller H, Menne J, Baumann M, Eulberg D.
CCL2 Inhibition with Emapticap Pegol (NOX-E36) in Type 2 Diabetic Patients with Albuminuria.

ISN World Congress of Nephrology
2015, Cape Town

Benedetti E, Duchemin N, Bethge L, Vonhoff S, Klussmann S, Vasseur JJ, Cossy J, Smietana M, Arseniyadis S.
DNA-cellulose: an economical, fully recyclable and highly effective chiral biomaterial for asymmetric catalysis.
Chem. Comm. 2015, 51(28), 6076-9.
read abstract on

Hoehlig K, Bethge L, Klussmann S.
Stereospecificity of Oligonucleotide Interactions Revisited: No Evidence for Heterochiral Hybridization and Ribozyme/DNAzyme Activity.
PLoS One. 2015, 10(2), e0115328.
read abstract on

Hoehlig K, Johnson KW, Pryazhnikov E, Maasch C, Clemens-Smith A, Purschke W, Vauléon S, Buchner K, Jarosch F, Khiroug L, Vater A, Klussmann S.
A Novel CGRP-neutralizing Spiegelmer Attenuates Neurogenic Plasma Protein Extravasation.
Br.J.Pharmacol. 2015.
read abstract on

Vater A, Klussmann S.
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics.
Drug Discovery Today. 2015, 20(1), 147-155.
read article on